International Journal of Medicine and Pharmaceutical Research Journal Home Page: www.pharmaresearchlibrary.com/ijmpr Research Article Open Access Development of Validated Stability Indicating Assay Method by RP-HPLC for Simultaneous Estimation of Azilsartan Medoximil and Chlorthalidone in Their Bulk and Combination Form S. Priyanka Yadav* 1, P. Sowjanya 2, Dr. Gampa Vijaya Kumar 3 1,2 KGR Institute of Technology and Management, Rampally, Kesara, Rangareddy, Telangana, India, 3 Professor and Head, Dept. of Pharmacy, KGR Institute of Technology and Management, Rampally, Kesara, Rangareddy, Telangana, India A B S T R A C T Method was established for simultaneous estimation of Azilsartan medoxomil and Chlorthalidone by RP-HPLC method. The chromatographic conditions were successfully developed for the separation of Azilsartan medoxomil and Chlorthalidone by using Agilent C18 5µm (4.6*250mm) column, flow rate was 1ml/min, mobile phase ratio was Methanol: sodium taurocholate (70:30%v/v) has been selected as mobile phase. If any buffer selected buffer ph should be between 2 (as to maintain biorelevant media specifications) Detection wave length was 238nm. The instrument used was Shimadzu LC-20 AD, SPD-M20A diode array detector, LC 20 software. The retention times were found to be 2.443 mins and 2.918 mins. The % purity of Azilsartan medoxomil and Chlorthalidone was found to be 100.7% and 101.4% respectively. The system suitability parameters for Azilsartan medoxomil and Chlorthalidone such as theoretical plates and tailing factor were found to be 1.7, 2114 and 1.7, 2931 the resolution was found to be 8.0.The analytical method was validated according to ICH guidelines (ICH, Q2 (R1)). Keywords: Agilent C18, Azilsartan medoxomil and Chlorthalidone, RP-HPLC method A R T I C L E I N F O CONTENTS 1. Introduction............................................................................... 183 2. Materials and Methods.......................................................................183 3. Results and discussion........................................................................183 4. Conclusion..................................................................................185 5. References.................................................................................185 Article History: Received 02 October 2017, Accepted 12 November 2017, Available Online 10 December 2017 *Corresponding Author Dr. Gampa Vijaya Kumar Professor and Head, Department of Pharmacy, KGR Institute of Technology &Management, Kesara, Rangareddy, Telangana, India Manuscript ID: IJMPR3472 PAPER-QR CODE Citation: Gampa Vijaya Kumar. et al, Development of Validated Stability Indicating Assay Method by RP-HPLC for Simultaneous Estimation of Azilsartan Medoximil and Chlorthalidone in Their Bulk and Combination Form. Int. J. Med. Pharm. Res., 2017, 5(6): 182-186. Copyright 2017 Gampa Vijaya Kumar. et al, This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution and reproduction in any medium, provided the original work is properly cited. International Journal of Medicine and Pharmaceutical Research 182
1. Introduction Azilsartan Medoxomil: Azilsartan medoxomil is an angiotensin II receptor antagonist indicated for the treatment of mild to moderate essential hypertension. Azilsartan bioavailability is 60%. Azilsartan medoxomil has so far been shown to be superior to olmesartan and valsartan in lowering blood pressure. Figure 1: Azilsartan Medoxomil Chlorithalidone: A benzene sulfonamide phthalimidine that tautomerizes to a benzophenones form. It is considered a thiazide-like diuretic. Chlorthalidone systemic is used in the treatment of Edema, High Blood Pressure. Absorbed relatively rapidly after oral administration. The major portion of the drug is excreted unchanged by the kidneys. Figure 2: Chlorithalidone and LOQ, Robustness parameters. All these parameters were validated according to ICH guidelines. Accuracy: The accuracy study was performed for 50%, 100% and 150 % for Azilsartan medoxomil and Chlorthalidone. Each level was injected in triplicate into chromatographic system. The area of each level was used for calculation of % recover y. Precision: The precision stud y was performed for five injections of Azilsartan medoxomil and Chlorthalidone. Each standard injection was injected in to chromatographic system. The area of each Standard injection was used for calculation of % RSD. Intermediate precision/ruggedness: The intermediate precision study was performed for five injections of Azilsartan medoxomil and Chlorthalidone. Each standard injection was injected into chromatographic system. The area of each standard injection was used for calculation of % RSD. Specificity: The system suitability for specificity was carried out to determine whether there is any interference of any impurities in retention time of analytical peak. Linearity The linearity study was performed for the concentration of 100ppm to 500ppm and1ppm to 5ppm level. Each level was injected into chromatographic system. The area of each level was used for calculation of correlation coefficient. Robustness: As part of the Robustness, deliberate change in the Flow rate, Mobile Phase composition, Temperature Variation was made to evaluate the impact on the method. Flow Rate: The robustness was performed for the flow rate variations from 0.8 ml/min to 1.2ml/min. Standard s o lu t io n 300 µg/ml of Chlorthalidone &3µg/ml of Azilsartan medoxomil was prepared and analyzed using the varied Mobile phase composition along with the actual mobile phase composition in the method. 2. Materials and Methods Materials and reagents: Azilsartan medoxomil and Chlorthalidone API, Potassium dihydrogen, sodium taurocholate, Methanol and water for HPLC. Method development: A combination of Methanol and sodium taurocholate in different compositions were tried to reduce the retention time to the minimum.mobile phase in the ratio of 70:30 was fixed as it gave accurate results and acceptable peak responses. Chromatographic conditions: Agilent C18 5µm (4.6*250mm) was used with Mobile phase Methanol: sodium taurocholate (70:30%v/v) with ambient column temperature. Flow rate was set at 1ml/min and detection wavelength is 238 nm in 10 min run time. Figure 3: Chromatogram showing accuracy 50%injection-1 3. Results and Discussion For the developed method, validation parameters checked were specificity, Linearity, Accuracy, Precision (Method precision and Intermediate precision), Sensitivity i.e., LOD Fig. 4: Chromatogram showing accuracy 100% injection-1 International Journal of Medicine and Pharmaceutical Research 183
Figure 5: Chromatogram of Standard Inj-1 Figure 10: Chromatogram for Robustness more organic Table 1: Details of Accuracy 50% Figure 6: Chromatogram of Standard Inj-1(ID Precision Table 2: Details of Accuracy 100% Figure 7: Chromatogram of sample Injection Figure 8: Chromatogram of standard Injection Table 3: Details of Accuracy 150 % Figure 9: Chromatogram for Robustness more flow International Journal of Medicine and Pharmaceutical Research 184
Table 4: Repeatability results of Chlorthalidone and Azilsartan medoxomil Table 5: Ruggedness results of Chlorthalidone and Azilsartan medoxomil 4. Conclusion A new method was established for simultaneous estimation of Azilsartan medoxomil and Chlorthalidone by RP-HPLC method. The chromatographic conditions were successfully developed for the separation of Azilsartan medoxomil and Chlorthalidone by using Agilent C18, 5µm (4.6*250mm) column, flow rate was 1ml/min, mobile phase ratio was Methanol: sodium taurocholate (70:30%v/v) has been selected as mobile phase. If any buffer selected buffer ph should be between 2 (as to maintain Bio relevant media specifications. Detection wave length was 238nm. The instrument used was Shimadzu LC- 20 AD, SPD-M20A diode array detector, LC 20 software The retention times were found to be 2.443 mins and 2.918 mins. The % purity of Azilsartan medoxomil and Chlorthalidone was found to be 100.7% and 101.4% respectively. The system suitability parameters for Azilsartan medoxomil and Chlorthalidone such as theoretical plates and tailing factor were found to be 1.7, 2114 and 1.7, 2931 the resolution was found to be 8.0.The analytical method was validated according to ICH guidelines (ICH, Q2(R1)). The linearity study for Azilsartan medoxomil and Chlorthalidone was found in concentration range of 1μg-5μg and 100μg-500μg and correlation coefficient (r2) was found to be 0.999 and 0.999, % mean recovery was found to be 100% and 100.5%, %RSD for repeatability was 2.0 and 2.0 0.2 % RSD for intermediate precision was 1.5 and 1.1 respectively. The precision study was precise, robust, and repeatable. LOD value was 2.95 and 3.04, and LOQ value was 9.87 and 10 respectively. Hence the suggested RP- HPLC method can be used for routine analysis o f Azilsartan medoxomil and Chlorthalidone in API and Pharmaceutical dosage form. 5. References [1] Sandeep kumar sohni, Robin kumar, mymoona akhtar, Chanda ranjan, Gita chawla. Development and validation of rp-hplc method for simultaneous estimation of azilsartan medoximil and chlorthalidone in bulk form and formulation using quality by design. International Journal of Pharmacy and Pharmaceutical Sciences, Vol 8, Issue 2, 2016. [2] Neelima kudumula and Y. Rajendra prasad. Development and validation of RP-HPLC method for the simultaneous estimation of azilsartan medoximil and cilnidipine in bulk and combined tablet dosage form. Pharmacophore 2014, vol. 5 (4), 442-450. [3] Madhukar A, N. Kannappan, Mahendra Kumar CB., RP-HPLC Method for the Simultaneous Estimation of chlorthalidone and Azilsartan in Bulk and Tablet dosage form in Biorelevant Media (FaSSIF), Journal of Scientific Research in Pharmacy 2014, 3(4) 135-142. [4] Tadeusz Inglot, Anna Gumieniczek, Paulina Mączka, Ewelina Rutkowska, New HPLC Method with Experimental Design and Fluorescence Detection for Analytical Study of Antihypertensive Mixture, chlorthalidone and Valsartan, American Journal of Analytical Chemistry, 2013, 4, 17-23. [5] Galia, E.; Nicolaides, E.; Hörter, D.; Löbenberg, R.; Reppas, C.; Dressman, J. B. Evaluation of Various Dissolution Media for Predicting In Vivo Performance of Class I and II Drugs. Pharm. Res. 1998, 15 (5), 698 705. [6] Gao Y, Li B, Zhu B, Liu D, Zhao H, A International Journal of Medicine and Pharmaceutical Research 185
liquid chromatography-tandem mass spectrometric assay for the antihypertensive agent azelnidipine in human plasma with application to clinical pharmacokinetics studies, Biomed Chromatogr. 2015, 29(7):970-4. [7] Madhukar A, N. Kannappan RP-HPLC Method for the Simultaneous Estimation of Azilsartan and chlorthalidone in Bulk and Tablet dosage form in Biorelevant Media (FaSSIF) Int.J. Pharm Tech Res. 2014-2015, 7(1), pp 172-184 [8] Nirav PM, Kaushal KC (2011), H. G.; Müllertz, A. Biorelevant dissolution media: Aggregation of Azilsartan and solubility of estradiol. J. Pharm. Sci. 2006, 95(2), 248 255. International Journal of Medicine and Pharmaceutical Research 186